Literature DB >> 25337982

Lower rotation speed stimulates sympathetic activation during continuous-flow left ventricular assist device treatment.

Teruhiko Imamura1, Koichiro Kinugawa, Daisuke Nitta, Takeo Fujino, Toshiro Inaba, Hisataka Maki, Masaru Hatano, Osamu Kinoshita, Kan Nawata, Shunei Kyo, Minoru Ono.   

Abstract

Although the suppression of sympathetic activity is an essential mission for the current heart failure treatment strategy, little is known about the relationship between the rotation speed setting and autonomic nervous activity during continuous-flow left ventricular assist device (LVAD) treatment. We evaluated 23 adult patients with sinus rhythm (36 ± 13 years) who had received continuous-flow LVAD and been followed at our institute between March 2013 and August 2014. Heart rate variability measurement was executed along with hemodynamic study at 3 rotation speeds (low, middle, and high) at 5 weeks after LVAD implantation. Lower rotation speed was associated with higher ratio of low-frequency over high-frequency spectral level (LF/HF), representing enhanced sympathetic activation (p < 0.05 by repeated analyses of variance). Among hemodynamic parameters, cardiac index was exclusively associated with LFNU = LF/(LF + HF), representing relative sympathetic activity over parasympathetic one (p < 0.05). After 6 months LVAD support at middle rotation speed, 19 patients with higher LFNU eventually had higher plasma levels of B-type natriuretic peptide and achieved less LV reverse remodeling. A logistic regression analysis demonstrated that lower LFNU was significantly associated with improvement of LV reverse remodeling (p = 0.021, odds ratio 0.903) with a cut-off level of 55 % calculated by the ROC analysis (AUC 0.869). In conclusion, autonomic activity can vary in various rotation speeds. Patients with higher LFNU may better be controlled at higher rotation speed with the view point to suppress sympathetic activity and achieve LV reverse remodeling.

Entities:  

Mesh:

Year:  2014        PMID: 25337982     DOI: 10.1007/s10047-014-0800-2

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  20 in total

1.  Studies on Starling's law of the heart. I. The circulatory response to acute hypervolemia and its modification by ganglionic blockade.

Authors:  R L FRYE; E BRAUNWALD
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

2.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

Review 3.  A rationale for the use of beta-blockers as standard treatment for heart failure.

Authors:  M Metra; S Nodari; A D'Aloia; L Bontempi; E Boldi; L D Cas
Journal:  Am Heart J       Date:  2000-03       Impact factor: 4.749

4.  Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control.

Authors:  S Akselrod; D Gordon; F A Ubel; D C Shannon; A C Berger; R J Cohen
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

Review 5.  Mechanism of action of beta-blocking agents in heart failure.

Authors:  M R Bristow
Journal:  Am J Cardiol       Date:  1997-12-04       Impact factor: 2.778

Review 6.  Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities.

Authors:  J S Floras
Journal:  Acta Physiol Scand       Date:  2003-03

7.  Late-onset right ventricular failure in patients with preoperative small left ventricle after implantation of continuous flow left ventricular assist device.

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Naoko Kato; Hironori Muraoka; Takeo Fujino; Toshiro Inaba; Hisataka Maki; Osamu Kinoshita; Masaru Hatano; Shunei Kyo; Minoru Ono
Journal:  Circ J       Date:  2014-01-16       Impact factor: 2.993

8.  The effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with non-ischaemic dilated cardiomyopathy.

Authors:  Robert S George; Emma J Birks; Andrew Cheetham; Carole Webb; Ryszad T Smolenski; Asghar Khaghani; Magdi H Yacoub; Andrew Kelion
Journal:  Eur J Heart Fail       Date:  2013-04-21       Impact factor: 15.534

9.  Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.

Authors:  Masatsugu Hori; Ryozo Nagai; Tohru Izumi; Masunori Matsuzaki
Journal:  Heart Vessels       Date:  2013-04-05       Impact factor: 2.037

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  3 in total

Review 1.  Journal of Artificial Organs 2015: the year in review : Journal of Artificial Organs Editorial Committee.

Authors:  Y Sawa; K Matsuda; E Tatsumi; G Matsumiya; T Tsukiya; T Abe; K Fukunaga; A Kishida; K Kokubo; T Masuzawa; A Myoui; M Nishimura; T Nishimura; T Nishinaka; E Okamoto; S Tokunaga; T Tomo; Y Yagi; T Yamaoka
Journal:  J Artif Organs       Date:  2016-02-20       Impact factor: 1.731

2.  Preoperative iodine-123 meta-iodobenzylguanidine imaging is a novel predictor of left ventricular reverse remodeling during treatment with a left ventricular assist device.

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Daisuke Nitta; Osamu Kinoshita; Kan Nawata; Minoru Ono
Journal:  J Artif Organs       Date:  2015-07-29       Impact factor: 1.731

3.  Optimization of pressure settings during adaptive servo-ventilation support using real-time heart rate variability assessment: initial case report.

Authors:  Teruhiko Imamura; Daisuke Nitta; Koichiro Kinugawa
Journal:  BMC Cardiovasc Disord       Date:  2017-01-05       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.